Barclays analyst Etzer Darout double upgraded Xencor (XNCR) to Overweight from Underweight with a price target of $23, up from $6. The firm has a more positive outlook on the company’s pipeline following updates at the AACR-NCI-EORTC Conference. XNCR’s recent updates for XmAb819, a first-in-class ENPP3 x CD3 bispecific T-cell engager in development for advanced clear cell renal cell carcinoma, and XmAb541 in CLDN6+ tumors were positive and exceeded expectations, the analyst tells investors in a research note. Barclays now values these programs at $6 per share.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor Inc.’s XmAb541: A Promising Phase 1 Study in Advanced Solid Tumors
- Xencor’s XmAb819 Study: A Promising Step in Cancer Treatment
- Xencor’s Promising NSCLC Study: A Potential Game-Changer?
- Xencor’s XmAb942 Study: A New Hope for Ulcerative Colitis?
- Xencor price target raised to $15 from $14 at BofA